HomeCompareAKSJF vs JNJ

AKSJF vs JNJ: Dividend Comparison 2026

AKSJF yields 1345.42% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKSJF wins by $261992149.87M in total portfolio value
10 years
AKSJF
AKSJF
● Live price
1345.42%
Share price
$2.95
Annual div
$39.69
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$261992149.90M
Annual income
$228,572,448,613,362.30
Full AKSJF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AKSJF vs JNJ

📍 AKSJF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKSJFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKSJF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKSJF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKSJF
Annual income on $10K today (after 15% tax)
$114,361.02/yr
After 10yr DRIP, annual income (after tax)
$194,286,581,321,357.97/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AKSJF beats the other by $194,286,581,317,371.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKSJF + JNJ for your $10,000?

AKSJF: 50%JNJ: 50%
100% JNJ50/50100% AKSJF
Portfolio after 10yr
$130996074.96M
Annual income
$114,286,224,309,025.86/yr
Blended yield
87.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AKSJF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKSJF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKSJFJNJ
Forward yield1345.42%2.13%
Annual dividend / share$39.69$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$261992149.90M$30.3K
Annual income after 10y$228,572,448,613,362.30$4,689.40
Total dividends collected$259531317.43M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AKSJF vs JNJ ($10,000, DRIP)

YearAKSJF PortfolioAKSJF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$145,242$134,542.38$10,592$272.30+$134.7KAKSJF
2$1,981,695$1,826,285.46$11,289$357.73+$1.97MAKSJF
3$25,408,205$23,287,791.77$12,123$472.89+$25.40MAKSJF
4$306,236,601$279,049,821.60$13,141$629.86+$306.22MAKSJF
5$3,470,938,760$3,143,265,596.63$14,408$846.81+$3470.92MAKSJF
6$37,009,528,330$33,295,623,856.57$16,021$1,151.60+$37009.51MAKSJF
7$371,395,302,942$331,795,107,629.62$18,122$1,588.22+$371395.28MAKSJF
8$3,509,174,205,017$3,111,781,230,868.68$20,930$2,228.20+$3509174.18MAKSJF
9$31,233,365,687,823$27,478,549,288,455.11$24,792$3,191.91+$31233365.66MAKSJF
10$261,992,149,899,333$228,572,448,613,362.30$30,274$4,689.40+$261992149.87MAKSJF

AKSJF vs JNJ: Complete Analysis 2026

AKSJFStock

Sberbank of Russia, together with its subsidiaries, provides corporate and retail banking products and services to individuals, small businesses, corporate clients, and financial institutions. The company offers deposit products; pension accounts; payment, transfer, brokerage, and asset management services; car, housing, education, and consumer loans; mortgages; debit and credit cards, and overdraft service; and refinancing products. It also provides derivative, financial instrument, foreign currency, precious metal, corporate structured, and commodities and securities products, as well as debt and capital markets funding, documentary, and other commission services. In addition, it offers life, property, bank card, accident, liability, trust management, investment and universal life, travel, and mutual investment funds insurance products, as well as individual pension plans and corporate pension programs. Additionally, the company provides business bank accounts, platform for exporters and importers, merchant acquiring and international trading services, and corporate cards for small businesses; and loans, investment products and capital markets services, fund investment services, and banking services for corporate clients. It also provides trade finance, interbank lending, currency risk hedging, and treasury services; deposits, custody services, and electronic trading systems; and settlement and cash collection services to financial institutions. As of December 31, 2020, the company operated 11 Regional banks and 14,162 branches in Russia. The company also has operations in 18 countries internationally. Sberbank of Russia was founded in 1841 and is headquartered in Moscow, Russia.

Full AKSJF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AKSJF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKSJF vs SCHDAKSJF vs JEPIAKSJF vs OAKSJF vs KOAKSJF vs MAINAKSJF vs ABBVAKSJF vs MRKAKSJF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.